Article Text

other Versions

PDF
Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?
  1. Yoshiteru Takekita1,2,
  2. Alessandro Serretti1
  1. 1Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
  2. 2Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
  1. Correspondence to Dr Yoshiteru Takekita, takekity{at}takii.kmu.ac.jp

Statistics from Altmetric.com

ABSTRACT FROM: Meltzer HY, Risinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry 2015;76:1085–90.

What is already known on this topic?

Depot antipsychotics may increase adherence to medication, reducing recurrence and rehospitalisation in schizophrenia.1 Aripiprazole lauroxil, a novel lipid ester prodrug of aripiprazole, is a long-acting injection (LAI) administered intramuscularly. After injection, it is metabolised by esterases to N-hydroxymethyl aripiprazole and then hydrolysed to aripiprazole. The available doses are 441, 662 and 882 mg every 4–6 weeks, corresponding to oral aripiprazole doses of 10, 15 and 20 mg/day or higher, respectively (those features add some flexibility to previously available formulations of aripiprazole LAI). Results from phase I studies about aripiprazole lauroxil …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.